Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
Karen L. Eskow Jaunarajs(University of Alabama at Birmingham), Randall W. Moreadith(The University of Texas Southwestern Medical Center), Michael D. Bentley(Minnesota State University, Mankato), Jonathan M. Brotchie(Atuka (Canada)), Paula Ravenscroft(Motac Neuroscience (United Kingdom)), Kunsang Yoon, Bekir Dizman, Tom H. Johnston(Atuka (Canada)), Rebecca Weimer, Michael P. Hill(Atuka (Canada)), David G. Standaert(University of Alabama at Birmingham), Tacey X. Viegas(Mirna Therapeutics (United States)), Zhihao Fang(Xi'an University of Architecture and Technology)
Cited by 68
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846
MHCII Is Required for -Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration
|Journal of Neuroscience|2013|424
Polyoxazoline: Chemistry, Properties, and Applications in Drug Delivery
|Bioconjugate Chemistry|2011|424
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease
|Nature Communications|2020|399